达托霉素
利奈唑啉
医学
万古霉素
重症监护医学
耐甲氧西林金黄色葡萄球菌
抗生素
肾毒性
金黄色葡萄球菌
内科学
微生物学
生物
细菌
遗传学
毒性
作者
Jack Chang,Ardita Tasellari,Jamie L. Wagner,Marc H. Scheetz
标识
DOI:10.1080/14787210.2023.2275663
摘要
INTRODUCTION: (MRSA) remains an important pathogen in the hospital setting and causes significant morbidity and mortality each year. Since the initial discovery over 60 years ago, vancomycin has remained a first-line treatment for many different types of MRSA infections. However, significant concerns related to target attainment and nephrotoxicity have spurred efforts to develop more effective agents in the last two decades. AREAS COVERED: Newer anti-MRSA antibiotics that have been approved since 2000 include linezolid, daptomycin, and ceftaroline. As clinical evidence has accumulated, these newer agents have become more frequently used, and some are now recommended as co-first-line options (along with vancomycin) in clinical practice guidelines. For this review, a scoping review of the literature was conducted to support our findings and recommendations. EXPERT OPINION: Vancomycin remains an important standard of care for MRSA infections but is limited with respect to nephrotoxicity and rapid target attainment. Newer agents such as linezolid, daptomycin, and ceftaroline have specific indications for treating different types of MRSA infections; however, newer agents also have unique attributes which require consideration during therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI